1. Home
  2. ALDF vs NMRA Comparison

ALDF vs NMRA Comparison

Compare ALDF & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALDF
  • NMRA
  • Stock Information
  • Founded
  • ALDF 2024
  • NMRA 2019
  • Country
  • ALDF United States
  • NMRA United States
  • Employees
  • ALDF N/A
  • NMRA N/A
  • Industry
  • ALDF
  • NMRA
  • Sector
  • ALDF
  • NMRA
  • Exchange
  • ALDF NYSE
  • NMRA Nasdaq
  • Market Cap
  • ALDF 296.6M
  • NMRA 287.6M
  • IPO Year
  • ALDF 2024
  • NMRA 2023
  • Fundamental
  • Price
  • ALDF $10.03
  • NMRA $1.80
  • Analyst Decision
  • ALDF
  • NMRA Strong Buy
  • Analyst Count
  • ALDF 0
  • NMRA 6
  • Target Price
  • ALDF N/A
  • NMRA $20.67
  • AVG Volume (30 Days)
  • ALDF 2.1K
  • NMRA 1.9M
  • Earning Date
  • ALDF 01-01-0001
  • NMRA 03-06-2025
  • Dividend Yield
  • ALDF N/A
  • NMRA N/A
  • EPS Growth
  • ALDF N/A
  • NMRA N/A
  • EPS
  • ALDF N/A
  • NMRA N/A
  • Revenue
  • ALDF N/A
  • NMRA N/A
  • Revenue This Year
  • ALDF N/A
  • NMRA N/A
  • Revenue Next Year
  • ALDF N/A
  • NMRA N/A
  • P/E Ratio
  • ALDF $79.36
  • NMRA N/A
  • Revenue Growth
  • ALDF N/A
  • NMRA N/A
  • 52 Week Low
  • ALDF $9.98
  • NMRA $1.60
  • 52 Week High
  • ALDF $11.46
  • NMRA $21.00
  • Technical
  • Relative Strength Index (RSI)
  • ALDF N/A
  • NMRA 27.76
  • Support Level
  • ALDF N/A
  • NMRA $1.61
  • Resistance Level
  • ALDF N/A
  • NMRA $1.80
  • Average True Range (ATR)
  • ALDF 0.00
  • NMRA 0.11
  • MACD
  • ALDF 0.00
  • NMRA 0.23
  • Stochastic Oscillator
  • ALDF 0.00
  • NMRA 51.28

About ALDF ALDEL FINL II INC

Aldel Financial II Inc is a blank check company.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Share on Social Networks: